Pay in 4 interest-free payments of $6.12 Learn more
Ships within 48 hours · Estimated delivery Oct 9 - Oct 14
Awareness of genetic predispositions to ageing supports personalised recommendations that help sustain optimal health and quality of life
NEW: Eli Lilly and Company's retatrutide, a first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist, met all primary and key secondary endpoints in the phase 3 TRIUMPH-4 trial in adults with obesity or overweight and knee osteoarthritis, and without diabetes, as an adjunct to healthy diet and physical activity
Most trials are in Phase 3 (56%)
A este grupo se han sumado recientemente otros compuestos en etapas tempranas y medias de desarrollo clnico, como los agonistas orales de ASCEND Therapeutics y los programas de Viking Therapeutics, que han mostrado resultados iniciales prometedores en estudios de fase 1 y fase 2
2020 Mar 10;13(3):e232241
US$ 25.59
US$ 23.41
_1772706284.jpg)
US$ 29.34
